NASDAQ:NTRA Natera (NTRA) Stock Forecast, Price & News $49.16 -1.37 (-2.71%) (As of 09/20/2023 ET) Add Compare Share Share Today's Range$48.89▼$51.3150-Day Range$43.40▼$62.5252-Week Range$34.00▼$63.00Volume1.08 million shsAverage Volume1.12 million shsMarket Capitalization$5.63 billionP/E RatioN/ADividend YieldN/APrice Target$70.22 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Natera MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside42.8% Upside$70.22 Price TargetShort InterestBearish5.85% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 5 Articles This WeekInsider TradingSelling Shares$1.96 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.03) to ($2.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 starsMedical Sector383rd out of 961 stocksMedical Laboratories Industry12th out of 24 stocks 3.5 Analyst's Opinion Consensus RatingNatera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $70.22, Natera has a forecasted upside of 42.8% from its current price of $49.16.Amount of Analyst CoverageNatera has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.85% of the outstanding shares of Natera have been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Natera has recently decreased by 1.62%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NTRA. Previous Next 3.8 News and Social Media Coverage News SentimentNatera has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Natera this week, compared to 4 articles on an average week.Search Interest10 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat Follows4 people have added Natera to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,962,053.00 in company stock.Percentage Held by InsidersOnly 9.42% of the stock of Natera is held by insiders.Percentage Held by Institutions92.59% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($4.03) to ($2.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -10.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -10.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 6.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Natera (NASDAQ:NTRA) StockNatera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Read More NTRA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NTRA Stock News HeadlinesSeptember 18, 2023 | finance.yahoo.comNatera Announces Senior Leadership AppointmentsSeptember 14, 2023 | finance.yahoo.comUnveiling Natera (NTRA)'s Value: Is It Really Priced Right? A Comprehensive GuideSeptember 21, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 14, 2023 | finance.yahoo.comNatera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant SettingSeptember 11, 2023 | americanbankingnews.comInsider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells $295,350.00 in StockSeptember 11, 2023 | americanbankingnews.comNatera, Inc. (NASDAQ:NTRA) Given Average Recommendation of "Buy" by BrokeragesSeptember 7, 2023 | msn.comNatera down 3%, prices $250M follow-on offeringSeptember 7, 2023 | markets.businessinsider.comNatera Prices Follow-On Offering At $55/share, Totaling $250 MlnSeptember 21, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 7, 2023 | finance.yahoo.comNatera Announces Pricing of $250 Million Follow-On OfferingSeptember 6, 2023 | barrons.comNatera Inc.September 5, 2023 | finance.yahoo.comNatera (NTRA) Reported Solid Quarterly Revenue Despite a Share Price DeclineSeptember 2, 2023 | uk.finance.yahoo.comNatera, Inc. (NTRA) stock price, news, quote & history – Yahoo FinanceAugust 23, 2023 | fool.comNatera (NASDAQ: NTRA)August 16, 2023 | finance.yahoo.comNatera’s Prospera™ Lung Transplant Assessment Test Granted Medicare CoverageAugust 15, 2023 | seekingalpha.comNatera: Strong Growth Amidst Profitability ChallengesAugust 8, 2023 | msn.comMorgan Stanley Maintains Natera (NTRA) Overweight RecommendationAugust 8, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for NateraAugust 5, 2023 | finance.yahoo.comNatera, Inc. (NASDAQ:NTRA) Q2 2023 Earnings Call TranscriptAugust 4, 2023 | seekingalpha.comNatera, Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 3, 2023 | finance.yahoo.comNatera Reports Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comNatera to Participate in Canaccord Genuity 43rd Annual Growth ConferenceAugust 2, 2023 | benzinga.comNatera Earnings PreviewJuly 31, 2023 | businesswire.comNatera Files Patent Infringement Suit Against NeoGenomicsJuly 28, 2023 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for Natera (NTRA)July 28, 2023 | finance.yahoo.comNatera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal CancerJuly 27, 2023 | finance.yahoo.comNatera to Report its Second Quarter 2023 Results on August 3rdSee More Headlines Receive NTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter. Email Address NTRA Company Calendar Last Earnings8/03/2023Today9/21/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTRA CUSIPN/A CIK1604821 Webwww.natera.com Phone(650) 249-9090FaxN/AEmployees3,018Year FoundedN/APrice Target and Rating Average Stock Price Forecast$70.22 High Stock Price Forecast$80.00 Low Stock Price Forecast$60.00 Forecasted Upside/Downside+42.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($4.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-547,800,000.00 Net Margins-54.97% Pretax Margin-54.92% Return on Equity-88.47% Return on Assets-41.19% Debt Debt-to-Equity Ratio0.47 Current Ratio3.85 Quick Ratio3.69 Sales & Book Value Annual Sales$820.22 million Price / Sales6.87 Cash FlowN/A Price / Cash FlowN/A Book Value$7.23 per share Price / Book6.80Miscellaneous Outstanding Shares114,600,000Free Float103,806,000Market Cap$5.63 billion OptionableOptionable Beta1.11 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Matthew Rabinowitz Ph.D. (Age 50)Co-Founder & Exec. Chairman Comp: $441.58kMr. Steven Leonard Chapman (Age 44)CEO, Pres & Director Comp: $1.15MMr. Michael B. Brophy M.B.A. (Age 43)Chief Financial Officer Comp: $611.35kMr. Daniel Rabinowitz L.L.M. (Age 54)LL.M., Sec. & Chief Legal Officer Comp: $566.03kMr. Jonathan Sheena M.Eng. (Age 50)Co-Founder & Director Ms. Olesya A. Anisimova CPAChief Accounting OfficerMr. Rishi KackerChief Technology OfficerMr. Eric A. EvansChief Scientific OfficerMr. Jerry DiffleyChief Compliance & Privacy OfficerMr. Phil GrinnellVP of SalesMore ExecutivesKey CompetitorsGuardant HealthNASDAQ:GHFortreaNASDAQ:FTRERadNetNASDAQ:RDNTExact SciencesNASDAQ:EXASQuest DiagnosticsNYSE:DGXView All CompetitorsInsiders & InstitutionsJonathan SheenaSold 5,000 sharesTotal: $295,350.00 ($59.07/share)Jonathan SheenaSold 10,000 sharesTotal: $600,100.00 ($60.01/share)Perceptive Advisors LLCSold 301,945 shares on 8/24/2023Ownership: 0.354%Comerica BankBought 5,213 shares on 8/22/2023Ownership: 0.005%California State Teachers Retirement SystemBought 1,887 shares on 8/21/2023Ownership: 0.113%View All Insider TransactionsView All Institutional Transactions NTRA Stock - Frequently Asked Questions Should I buy or sell Natera stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NTRA shares. View NTRA analyst ratings or view top-rated stocks. What is Natera's stock price forecast for 2023? 6 equities research analysts have issued 1 year price targets for Natera's shares. Their NTRA share price forecasts range from $60.00 to $80.00. On average, they predict the company's share price to reach $70.22 in the next year. This suggests a possible upside of 42.8% from the stock's current price. View analysts price targets for NTRA or view top-rated stocks among Wall Street analysts. How have NTRA shares performed in 2023? Natera's stock was trading at $40.17 on January 1st, 2023. Since then, NTRA stock has increased by 22.4% and is now trading at $49.16. View the best growth stocks for 2023 here. When is Natera's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our NTRA earnings forecast. How were Natera's earnings last quarter? Natera, Inc. (NASDAQ:NTRA) announced its quarterly earnings data on Thursday, August, 3rd. The medical research company reported ($0.97) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.12. The medical research company had revenue of $261.40 million for the quarter, compared to the consensus estimate of $241.67 million. Natera had a negative net margin of 54.97% and a negative trailing twelve-month return on equity of 88.47%. The firm's quarterly revenue was up 31.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.50) earnings per share. What ETFs hold Natera's stock? ETFs with the largest weight of Natera (NASDAQ:NTRA) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Alger 35 ETF (ATFV), Alger Mid Cap 40 ETF (FRTY), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Health Care AlphaDEX Fund (FXH), Principal Healthcare Innovators ETF (BTEC) and VanEck Biotech ETF (BBH). What guidance has Natera issued on next quarter's earnings? Natera updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.01 billion-$1.03 billion, compared to the consensus revenue estimate of $1.01 billion. What is Steve Chapman's approval rating as Natera's CEO? 158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN). When did Natera IPO? (NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. What is Natera's stock symbol? Natera trades on the NASDAQ under the ticker symbol "NTRA." Who are Natera's major shareholders? Natera's stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (2.71%), Alliancebernstein L.P. (2.68%), Kynam Capital Management LP (2.53%), Geode Capital Management LLC (1.44%), Principal Financial Group Inc. (1.29%) and Marshall Wace LLP (1.23%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens. View institutional ownership trends. How do I buy shares of Natera? Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Natera's stock price today? One share of NTRA stock can currently be purchased for approximately $49.16. How much money does Natera make? Natera (NASDAQ:NTRA) has a market capitalization of $5.63 billion and generates $820.22 million in revenue each year. The medical research company earns $-547,800,000.00 in net income (profit) each year or ($4.82) on an earnings per share basis. How many employees does Natera have? The company employs 3,018 workers across the globe. How can I contact Natera? Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The official website for the company is www.natera.com. The medical research company can be reached via phone at (650) 249-9090 or via email at mbrophy@natera.com. This page (NASDAQ:NTRA) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.